Investor Relations

Welcome to our dedicated page for investor resources. You will find everything you need if you want to invest in pioneering medical science.

Dedicated to solving some of today’s biggest public health challenges, bioMérieux has the focus and the capabilities to discover, develop, and commercialize advanced medical diagnostics solutions that have an impact on people’s lives. We combine the dynamism of a technology-fueled company with the long-term thinking of our founding family. It is this alliance that shapes our strategy and success.

A values-based company, we aim for strong and sustainable performance that benefits our shareholders, our employees, and society.

Investors

Third-Quarter 2022 Business Review

Reported growth of +4.4% over the first nine months of the year:
- €2,560 million in sales
- -1.9% at constant exchange rates and scope of consolidation
In Q3, higher than expected BIOFIRE^® respiratory panels demand within a context of endemicity of COVID-19
Robust performance of BIOFIRE^® non-respiratory panels, Clinical microbiology and Industrial applications over the quarter
Guidance in the upper end of the announced ranges on August, 31^st

“bioMérieux performed well during the third quarter of 2022. This performance demonstrates the resilience of our syndromic offer and the relevancy of our innovative portfolio of solutions dedicated to the fight against antimicrobioal resistance. We confirm our 2022 objectives, targeting now the upper end of the ranges of our August guidance.”

Alexandre Mérieux, Chairman and CEO